NEOS Investment Management LLC Acquires 9,099 Shares of Zoetis Inc. $ZTS

NEOS Investment Management LLC boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 14.5% during the second quarter, Holdings Channel reports. The fund owned 71,746 shares of the company’s stock after purchasing an additional 9,099 shares during the period. NEOS Investment Management LLC’s holdings in Zoetis were worth $5,156,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in ZTS. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Zoetis in the second quarter valued at $25,000. Dunhill Financial LLC raised its position in shares of Zoetis by 519.3% in the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after purchasing an additional 296 shares during the period. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis during the 4th quarter worth about $25,000. Cassaday & Co Wealth Management LLC bought a new stake in shares of Zoetis during the 1st quarter worth about $28,000. Finally, Root Financial Partners LLC boosted its holdings in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. BNP Paribas Exane lowered their price target on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, August 11th. Barclays reduced their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday, July 1st. William Blair reaffirmed a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. TD Cowen lowered their target price on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 25th. Finally, Argus restated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $107.43.

Zoetis Price Performance

Shares of Zoetis stock opened at $75.70 on Monday. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The stock has a market capitalization of $31.28 billion, a price-to-earnings ratio of 12.47, a price-to-earnings-growth ratio of 1.77 and a beta of 0.73. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $155.15. The company has a 50-day simple moving average of $75.53 and a two-hundred day simple moving average of $93.61.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the prior year, the business posted $1.76 EPS. The business’s revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts forecast that Zoetis Inc. will post 6.2 EPS for the current year.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.